Advances in the Treatment of COVID-19 Phase 11


Time :

2022-12-16

Significant progress! Important cause of death or poor prognosis in critically ill COVID-19 patients discovered

Significant progress! Important cause of death or poor prognosis in critically ill COVID-19 patients discovered
Zhongnan Hospital of Wuhan University passed 48 cases in Zhongnan Hospital of Wuhan University and Leishenshan of Wuhan
Screening and clinical study of lower extremity deep vein thrombosis in patients treated in the hospital's intensive care unit
The incidence of deep venous thrombosis in critically ill patients with COVID-19 is as high as 85.4%. The widespread formation of deep venous thrombosis may be an important reason for the death or poor prognosis of critically ill patients with COVID-19. The results were published online in Circulation, the world's top cardiovascular journal.
Professor Cai Lin's research group from the Department of Spine and Bone Tumor Surgery, Zhongnan Hospital, Wuhan University analyzed and studied 48 critically ill patients with COVID-19. Except for one patient with contraindications to anticoagulation, all patients received routine anticoagulation by subcutaneous low molecular weight heparin injection once a day. However, even under the condition of drug thromboprophylaxis, 41 patients (85.4%) were still detected to have lower extremity deep vein thrombosis, of which 36 (75%) were located in distal veins and 5 (10.4%) in proximal veins. All patients showed abnormal levels of inflammatory indicators. Of the 29 patients who received mechanical ventilation, 18 underwent endotracheal intubation.
Severe infection and inflammation may be important factors in the development of deep venous thrombosis in severe COVID-19 patients. In addition, bed braking, mechanical ventilation, and venous catheterization may all be high risk factors for thrombosis in severe COVID-19 patients.
The results of this study were the first to report the high incidence of lower extremity deep vein thrombosis in severe COVID-19 patients internationally, which provides a new direction for more in-depth research on the cause of death and pathogenic mechanism of COVID-19 patients in the future. It also provides certain guiding significance for the treatment of COVID-19, especially critically ill COVID-19, which is still spreading worldwide.
Zhongnan Hospital of Wuhan University is the only designated hospital in Hubei Province to treat COVID-19 patients in the "1 + 3" model in the fight against the COVID-19 epidemic. Zhongnan Hospital of Wuhan University has successively taken over Wuhan Seventh Hospital, Wuhan Living Room Shelter Hospital, and Wuhan Leishenshan Hospital, providing a total of more than 5,400 beds. In the global COVID-19 epidemic science and technology contribution ranking released by Digital Science, Zhongnan Hospital of Wuhan University is the second most published clinical hospital for COVID-19 research papers in the world, second only to Massachusetts General Hospital in the United States.